Cardamyst (etripamil) is a nose spray that helps treat sudden episodes of fast heartbeats, known as paroxysmal supraventricular tachycardia (PSVT). PSVT is a type of abnormal heart rhythm where your ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response ...

The investigational intranasal L-type calcium channel blocker etripamil continues to be well tolerated and effective for self-treating recurrent episodes of paroxysmal supraventricular tachycardia ...

Milestone Pharmaceuticals (NASDAQ:MIST) shares jumped roughly 35% after the U.S. Food and Drug Administration approved CARDAMYST, the first nasal spray that patients can self-administer to treat ...

A sudden, rapid heart rate will send many to the emergency room. Every year, more than 140,000 emergency room visits are related to a specific type of increased heart rate called paroxysmal ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a rapid-acting nasal spray for the treatment of acute symptomatic paroxysmal supraventricular ...

Credit: Milestone Pharmaceuticals Cardamyst is supplied as a carton of 2 disposable nasal spray devices, each delivering 2 sprays containing a total of 70mg of etripamil. Cardamyst is expected to be ...

Etripamil is a calcium channel blocker designed to be administered intranasally to treat episodes of PSVT in an at-home setting. The Food and Drug Administration (FDA) has accepted for review the New ...

Milestone Pharmaceuticals announced a Commercial Launch Plan investor event, indicating proactive engagement with investors and transparency about its upcoming strategies. The event will detail the ...

MONTREAL and CHARLOTTE, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of ...